Supplementary Table 1. Peri-procedural and follow-up clinical outcomes

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
|  | BAV | | | TAV | | P value |
|  | BAV (Type 0)  n = 56 | BAV (Type 1)  n = 27 | Total  n = 83 | | n = 121 |
| Mortality |  |  |  | |  |  |
| In-hospital | 0(0.0) | 0(0.0) | 0(0.0) | | 1(0.8) | 1.000 |
| 30-day | 0(0.0) | 0(0.0) | 0(0.0) | | 1(0.8) | 1.000 |
| Stroke | 2(3.6) | 0(0.0) | 2(2.4) | | 2(1.7) | 0.704 |
| Disabling stroke | 0(0.0) | 0(0.0) | 0(0.0) | | 2(1.7) | 0.515 |
| Non-disabling stroke | 2(3.6) | 0(0.0) | 2(2.4) | | 0(0.0) | 0.164 |
| Vascular Complication | 5(8.9) | 2(7.4) | 7(8.4) | | 10(8.3) | 1.000 |
| New Af | 1(1.8) | 0(0.0) | 1(1.2) | | 4(3.3) | 0.412 |
| New Pacemaker | 0(0.0) | 0(0.0) | 0(0.0) | | 4(3.3) | 0.147 |
| Medication |  |  |  | |  | 0.953 |
| Anticoagulation | 8(14.3) | 5(18.5) | 13(15.7) | | 21(17.4) |  |
| Antiplatelet | 46(82.1) | 22(81.5) | 68(81.9) | | 96(79.3) |  |
| No antithrombosis | 2(3.6) | 0(0.0) | 2(2.4) | | 4(3.3) |  |

# Data was presented by median(interquartile range).

\* Mann-Whitney U test was used.

Data are presented as no. (%). Af, atrial fibrillation; BAV, bicuspid aortic valve; CPB, cardiopulmonary bypass; SAVR, surgical transcatheter aortic valve replacement; TAV, tricuspid aortic valve.